Dicerna Pharmaceuticals, Inc. functions as a biopharmaceutical company primarily dedicated to the full spectrum of RNA interference (RNAi)-based drug development, from initial discovery to market commercialization. The firm leverages its exclusive GalXC RNAi platform to engineer therapeutic solutions for a diverse array of medical conditions. These include various liver-related ailments, spanning rare, cardiometabolic, viral, and chronic forms, alongside complement-mediated disorders, neurodegenerative diseases, and pain. Among its prominent development candidates are nedosiran, targeting primary hyperoxaluria; RG6346, designed for chronic hepatitis B virus infection; belcesiran, intended for deficiency-associated liver disease; and DCR-AUD, addressing alcohol use disorder. Dicerna has established significant collaborations with several leading pharmaceutical corporations, including Novo Nordisk A/S, F. Hoffmann-La Roche (both Ltd and Inc.), Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. Founded in 2006 and based in Lexington, Massachusetts, Dicerna Pharmaceuticals, Inc. has been operating as a subsidiary of Novo Nordisk A/S since December 27, 2021.